Dr. Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center discusses the Optimal Front-Line Treatment for mRCC
Toni K. Choueiri, MD Clinical Director and Kidney Cancer Center Director The Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute…
Ari Hakimi MD Assistant Professor Urologic Oncology Affiliate Department of Computational Biology MSKCC presents Genomic Characterization of Sarcomatoid Clear Cell…
Jianjun Gao, MD, PhD Department of Genitourinary Oncology MD Anderson Cancer Center presents Molecular Characterization of Renal Medullary Carcinoma at…
Gabriel G. Malouf, MD, PhD Assistant professor Department of medical oncology Pitié-Salpêtrière Hospital, Paris, France discusses Translocation Renal Cell Carcinomas:…
Laurence Albiges, MD, PhD Lank Center for Genitourinary Oncology presents Papillary Renal Cell Carcinoma at the Kidney Cancer Association meeting…
James Hsieh MD PhD MSKCC Translational Kidney Cancer Research Program (TKCRP) presents13thIKCS Chicago Rare Kidney Cancer:Chromophobe RCC at the Kidney…
Michael L. Blute Sr. MD Chief Urology MGH Walter S. Kerr Jr. Professor of Surgery Harvard Medical School presents Case…
Michael L. Blute Jr of MD Anderson presents the Recurrence After Surgery in Non-metastatic RCC with Thrombus; Risk Factors From…
Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology discusses Cytoreductive Nephrectomy at the Kidney Cancer Association meeting in…
Sarah P. Psutka MD Fellow in Urologic Oncology Mayo Clinic, Rochester, MN presents the Latest On IVC Tumor Thrombus at…
Jonathan Coleman, MD Memorial Sloan-Kettering Cancer Center Weill – Cornell University Medical College presents Kidney Cancer Management:The Role of Lymph…
At the iwNHL 2014, Prof Francesco D’Amore (Aarhus University, Aarhus, Denmark) interviews Dr Elaine Jaffe (National Cancer Institute, Maryland, USA)…
Thomas D. Atwell, MD presents Ablation of larger and recurrent tumors at the Kidney Cancer Association meeting in Chicago 2014
R. Houston Thompson, MD of the Mayo Clinic presents NCCN and AUA GUIDELINES FOR RCC: DO THEY EFFECTIVELY CAPTURE RECURRENCES…
Joel Prince of The University of Wisconsin School of Medicine and Public Health presents Patient and Tumor Characteristics Predict Indeterminate…
Jose A. Karam, MD Assistant Professor Department of Urology MD Anderson presents Locally Advanced RCC: Neoadjuvant Targeted Therapy
Tony Finelli MD, MSc, FRCSC GU Site Lead, Princess Margaret Cancer Center GU Lead, Cancer Care Ontario Associate Professor, University…
Lara Barbara – Breast Cancer Survivor NSHOA Treats Patients with Chemo and Hugs brought to you by The Community Oncology…
Michael Murray – Primary Goal for Everyone at NSHOA is Patient Care brought to you by The Community Oncology Alliance…
Dr. Ron Burkes commenting on the results of the Lux-Lung8 Trial from ESMO 2014
Dr. Natasha Leighl, lead study author, on the newsiest results on the activity of pembrolizumab in lung cancer
Dr. Edith Perez speaking on the expanded results of the ALTTO breast cancer trial
Dr. Sunil Verma providing a comprehensive update on the latest lung cancer updates from ESMO 2014
Don Marx – Care for Today, Research for Tomorrow brought to you by The Community Oncology Alliance (COA) and The…
Dr. Tewari at ESMO 2014 on latest advanced cervical cancer therapies
Dr. Teresa Petrella and Dr. Catalin Mihalcioiu speaking on combination therapies in melanoma.
Mark Levine – CFO North Shore Hematology Oncology Focused on Patient Care brought to you by The Community Oncology Alliance…
Immuno-Oncology: Shaping the Present, Transforming the Future and Raising the Bar in Oncology – from Best of ASCO Canada 2014
Nicole Gregory – The Chief Commercial Officer – What we do for our Patients brought to you by The Community…
Michael Mitrani – Guiding Patients Through the Benefits Maze brought to you by The Community Oncology Alliance (COA) and The…
Timothy A. Masterson, MD Assistant ProfessorDepartment of UrologyIndiana University Medical Center and Vitaly Margulis MD Associate Professor of Urology of…
Nicholas G. Cost, M.D.Assistant Professor, Department of Surgery, Division of Urology University of Colorado School of Medicine discusses Hereditary Syndromes…
Brian Shuch, MD Assistant Professor of Urology and Radiology Yale School of Medicine presents Management of Kidney Cancer in Young…
E. Jason Abel MD, FACS of the University of Wisconsin presents Renal mass biopsy for risk stratification in RCC: benefits…
Mark Purdue, PhDOntario Institute for Cancer Research discusses Epidemiology and Genomics of Renal Cell Carcinoma at the Kidney Cancer Association…
Projecting Individual Probability for Developing Renal Cell Cancer presented by Xifeng Wu, MD, PHD, Professor and ChairDepartment of Epidemiology Betty…
At the iwNHL 2014, Dr Rafael Fonseca (Mayo Clinic, Arizona, USA) interviews Prof Keith Stewart (Mayo Clinic, Arizona, USA) and…
At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Wolfram Brugger (University of Freiburg, Villingen-Schwenningen,…
At the iwNHL 2014, Dr Steven Rosen (City of Hope National Medical Center, California, USA) describes the progress made in…
At the iwNHL 2014, Dr Mathias Rummel (Justus-Liebig University-Hospital, Gießen, Germany) describes his research investigating the use of bendamustine plus…
At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency,…
At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency,…
At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency,…
Prof John Gribben (Barts Cancer Institute, London, UK) chairs a discussion with Dr Wyndham Wilson (National Cancer Institute, Bethesda, USA),…
Prof John Gribben (Barts Cancer Institute, London, UK) chairs a discussion with Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver,…
At the iwNHL 2014, Prof Michael Pfreundschuh (Saarland University Medical School, Homburg, Germany), Dr Rich Fisher (Fox Chase Cancer Center,…
At the iwNHL 2014, Prof Susan OBrien (MD Anderson Cancer Center, Texas, USA) and Prof Eva Kimby (Karolinska Institutet, Huddinge,…
At ESMO 2014, Dr Jennifer Temel is interviewed about the results of a phase III trial investigating the use of…
At ESMO 2014, Prof Tony Mok presents the results of the IMPRESS trial. This phase III trial showed that continuation…
At ESMO 2014, Prof Sandra Swain presents the results of the CLEOPATRA trial. This phase III trial in patients with…
During a press conference at ESMO 2014, Prof Frédéric Amant, University of Leuven, Leuven, Belgium, discusses his study on the…
At ESMO 2014, Prof Johan F. Vansteenkiste summarises the results of the MAGRIT trial, a phase III trial which showed…
During a press conference at ESMO 2014, Dr Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels, Belgium, presents the results of…
During a press conference at ESMO 2014, Dr Bernardo Leon Rapoport, The Medical Oncology Centre Rosebank, Johannesburg, South Africa, presents…
During the Saturday press conference at ESMO 2014, Professor David Currow describes results of Phase III data showing that a…
Results of the MPACT Trial (weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone) in patients with metastatic pancreatic cancer will be…
The objective of this webinar was to provide an overview of the available front-line therapeutic options for patients with metastatic…
A study published online in the August 2014 edition of the Annals of Surgical Oncology shows that BluePrint (Agendia Inc)…
Tamoxifen (Soltamox/Nolvadex®; AstraZeneca), an antagonist of the estrogen receptor ? in ER?-positive breast cancer has been effective in most patients.…
The immune system has the ability to recognize tumors and to stop or control their development through a process known…
For more free video updates go to www.oncologyeducation.com Incorporation of Bv into anthracycline and taxane containing adjuvant therapy does not…
To view more free videos – visit www.oncologyeducation.com Profiling of protein expression, gene copy variations and mutations identified clinically relevant…
For additional free GI/Colorectal Cancer video updates, please go to www.oncologyeducation.com Chemo/CET and chemo/BV equivalent in OS in pts KRAS…
Dr Kenneth Anderson (Dana Farber Cancer Institute, Boston, USA) chairs a discussion with Prof Gareth Morgan (The Royal Marsden Hospital,…
Dr Anderson (Dana Farber Cancer Institute, Boston, USA) chairs a discussion with Prof Palumbo (University of Torina, Torina, Italy), Prof…
Prof Keith Stewart (Mayo Clinic, Scottsdale, USA) chairs a discussion with Prof Gareth Morgan (The Royal Marsden Hospital, London, UK),…
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, tells the European Medical Journal about the possible enormous value…
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed…
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed…
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, speaks to the European Medical Journal from the 19th Congress…
Speaking to the European Medical Journal from the 19th Congress of the European Haematology Association (EHA) meeting, Prof. John Seymour…
Dr Kenneth Anderson, Multiple Myeloma Boston 2014 congress round-up
Prof. Peter Hillmen from Leeds Teaching Hospital, Leeds, UK, gives an update on the phase III results from the RESONATE…
Speaking to EMJ from the 19th Congress of the European Hematology Association (EHA 19) meeting, Prof. Paul Richardson , Dana-Farber…
Prof. Simon Rule from Plymouth Hospital, UK, discusses data presented at EHA19 on the second-generation oral BTK inhibitor, ONO-4059. One…
Prof. Valeria Santini, University of Florence Medical School, Italy, highlights novel mutational and genetic studies in MDS presented atEHA19 which…
Prof. Stephan Stilgenbauer from University of Ulm, Germany, defines ultra high-risk CLL (chronic lymphocytic leukemia) and comments on its implications…
Held annually in South Florida every January, The Symposium on Clinical Interventional Oncology (CIO) features a concentrated 2-day program renowned…
When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University…
Prof David Cameron from The Edinburgh Cancer Research Centre is committed to identifying potential new approaches to treating and preventing…
A retrospective study of the effect of extending mammography to age 75 was performed in the Netherlands to use data…
A detailed analysis of risk factors including genomic markers of women with breast cancer has revealed that three-year mammographic screening…
A massive Oxford meta-analysis they have completed has shown that adjuvant radiotherapy gives absolute benefits in terms of progression-free and…
Dr Poortmans presented a late breaking abstract at a workshop on the regional control of breast cancer, along with speakers…
Dr. Mark Socinski is a Professor of Medicine, University of Pittsburgh School of Medicine. In this video, he answers common…
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Gestione degli effetti collaterali delle terapie e delle complicanze post-chirurgiche 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna,…
Stato dell’arte e ricerca clinica attuale (SECONDA PARTE) 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna 29 marzo…
Il percorso della ricerca nei GIST in laboratorio. 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Caso clinico 3: terapia con Regorafenib in terza linea di trattamento. 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna,…
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Don Sharpe talks to Terri Guidi, MBA of Oncology Management and Consulting about a real life case study of an…
Don Sharpe sits down with Ted Okon the Executive Director of The Community Oncology Alliance and they talk about what’s…
Don Sharpe talks to Ricky Newton, CPA of Cancer Specialists of Tidewater about how to understand the business issue of…
Don Sharpe talks to Dr. Jeff Vacirca, MD of North Shore Hematology and Oncology concerning the Effects of Sequestration to…
Don Sharpe of OBR interviews Dr. Ira Klein, MD where he asks What is Gene Forward and Gene Backward?
Don Sharpe sits down with Dr. Brian Van Tine, MD PhD or Washington University to talk about Management and Treatment…
Don Sharpe discusses the Payer Perspective on Molecular Testing with Dr. Micheal Kolodziej, MD from Aetna at the COA annual…
Don Sharpe of OBR talks about the variances in genetic testing and how that may affect health care decisions with…
Don Sharpe talks about Molecular Testing for Cancer from a Payer Perspective with Dr. Sundeep Reddy, MD (Caris Life Sciences)…
Don Sharpe of OBR discusses the topic What’s Making Your Oncologist Sick? with Dr. Joseph Lynch, MD at the COA…
Don Sharpe talks to Rebecca Bechhold, MD about Integrating Palliative Care and Oncology from the COA annual meeting in Orlando.
Don Sharpe of OBR discusses The Genetic Science Behind Heredity Colon Cancer Syndromes with Dr. Larry Geier, MD at the…
Don Sharpe of OBR discusses The Medical Home past and future with Bo Gamble, Director of Strategic Practice Initiatives, Community…
Don Sharpe of OBR discusses how an oncology practice get’s started with The Medical Home model and the implemenation process…
Don Sharpe of OBR discusses the progress for payers who are using The Medical Home model with Gordon Kuntz of…
Don Sharpe of OBR talks to Dr. Daniel McKeller, MD of the Commission on Cancer about the report on The…
Don Sharpe talks to Stuart Genschaw, Exec. Dir. of Cancer & Hematology Centers of Western Michigan about innovation within oncology…
Don Sharpe asks the question Why are you embracing payment reform at The Center for Cancer and Blood Disorders to…
Don Sharpe discusses the success at Advanced Medical Specialties using Accountable Care Organization (ACO) with Dr. Leonard Kalman, MD from…
Don Sharpe talks to Dr. Barbara McAneny, MD from New Mexico Cancer Center about the CMMI Award and setting up…
Don Sharpe talks about the importance of cancer patient advocacy from the point of view of a medical oncologists Dr.…
Don Sharpe discusses Dr Erin Dunbar, MD or Piedmont Healthcare her presentation entitled “Good News from the Oncologist” at the…
Don Sharpe of OBR talks to Dr. Lucio Gordon, MD of Florida Cancer Specialists about the role of IT, Electronic…
Don Sharpe talks to Angel Aslo, PharmD about the role of in house pharmacies within the community oncology setting.
Don Sharpe discusses with Ray Bailey, PharmD the role in which in house pharmacies play within oncology practices.
Don Sharpe of OBR discusses a surprise announcement from Dr. Siddhartha Mukherjee author and Pulitzer prize winner for The Emperor…
Don Sharpe of OBR discusses molecular profiling with Dr. John Powderly of Carolina BioOncology Institute at COA.
Don Sharpe discusses with Ray Bailey, PharmD the role in which in house pharmacies play within oncology practices.
Don Sharpe of OBR discusses a surprise announcement from Dr. Siddhartha Mukherjee author and Pulitzer prize winner for The Emperor…
Don Sharpe of OBR discusses molecular profiling with Dr. John Powderly of Carolina BioOncology Institute at COA.
Stato dell’arte e ricerca clinica attuale (PRIMA PARTE) 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna 29 marzo…
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna 29 marzo 2014
Terapia Sunitinib: verso la personalizzazione della cura. 7° Riunione Annuale A.I.G. Associazione Italiana GIST Onlus, Bologna 29 marzo 2014
Dott. Paolo G. Casali, Responsabile SSD Oncologia Medica Tumori Mesenchimali dell’Adulto, Fondazione IRCCS Istituto Nazionale Tumori – Milano 7° Riunione…
Messaggio dell’Associazione e Introduzione ai lavori 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna 29 marzo 2014
Imatininb nella terapia pre-operatoria, adiuvante e di prima linea nel trattamento del GIST 7° Riunione Nazionale A.I.G. Associazione Italiana GIST…
Benvenuto e introduzione 7° Riunione Nazionale di A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
SAN FRANCISCOThe ability of cancer cells to evolve clonally into molecularly distinct strands needs to be considered when selecting targeted…
NEW ORLEANSHigh remission rates with extended survival are being achieved in patients who had failed all other therapies including allogeneic…
LONDON Researchers have shown that endometrial cancer and hopefully ovarian cancer too could potentially be detected much earlier than at…
ORLANDO, FLORIDAPatients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from…
SAN FRANCISCONew research has shown the alpha-emitting drug radium 233 to be a benign therapy with no major toxicities while…
SAN FRANCISCO The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in…
NEW ORLEANSA new oral tyrosine kinase inhibitor drug idelalisib has proved effective and to have low toxicity in patients with…
The rare, fatal lympho-proliferative condition: Multicentric Castleman’s Disease MCD could soon be treatable following findings announced at the American Society…
WASHINGTON DCA new type of immunotherapy has brought responses in children with acute lymphoblastic leukaemia in relapse who had no…
CAMBRIDGE, UKA new blood test promises quicker assessment of treatment efficacy in patients with metastatic breast cancer. Dr Dana Tsui…
ORLANDO, FLORIDAA decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients…
ORLANDO, FLORIDAPatients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr…
3-9-14 9:01am
3-9-14 8:50am
3-7-14 10:54 FLV
3-7-14 3:10pm
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Angela Dispenzieri discusses who should…